Akeso Secures Fifth NMPA Breakthrough Designation for Biliary Cancer Therapy
Event summary
- Akeso received its fifth Breakthrough Therapy Designation (BTD) from the NMPA for ivonescimab, a bispecific antibody, in combination with chemotherapy for first-line treatment of advanced biliary tract cancer (BTC).
- The Phase III clinical study (AK112-309/HARMONi-GI1) evaluating ivonescimab plus chemotherapy versus durvalumab plus chemotherapy has completed patient enrollment.
- Phase 1b/II data showed ivonescimab plus chemotherapy achieved a 63.6% Objective Response Rate (ORR) and 100% Disease Control Rate (DCR), with mPFS of 8.5 months and mOS of 16.8 months.
- This BTD follows four previous designations from the NMPA, three for lung cancer and one for triple-negative breast cancer (TNBC).
The big picture
Akeso's repeated BTD designations highlight the growing importance of China's regulatory pathway for innovative therapies. The company's Tetrabody platform appears to be generating promising candidates across multiple cancer types, but the Phase III trial results will be the ultimate determinant of commercial success. The competition in the BTC space is intensifying, and Akeso’s ability to demonstrate a meaningful clinical advantage will be crucial for capturing market share.
What we're watching
- Regulatory Speed
- The accelerated review process afforded by the BTD will be a key indicator of the NMPA's commitment to innovative therapies and could set a precedent for future approvals.
- Phase III Results
- The success of the ongoing Phase III trial, particularly in demonstrating superiority over durvalumab plus chemotherapy, will be critical for ivonescimab's commercial viability in China.
- Market Adoption
- How quickly physicians and patients adopt ivonescimab, even with accelerated approval, will depend on its perceived efficacy and safety profile relative to existing treatment options.
Related topics